Skip to main content
Clinical Trials/EUCTR2011-003652-39-DK
EUCTR2011-003652-39-DK
Active, not recruiting
Phase 1

Exercise induced bronchoconstriction in children – a single dose of montelukast as alternative to regular daily doses.

Karen Schow Jensen0 sites32 target enrollmentJuly 31, 2012

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Exercise induced asthma
Sponsor
Karen Schow Jensen
Enrollment
32
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 31, 2012
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Karen Schow Jensen

Eligibility Criteria

Inclusion Criteria

  • Written informed consent from child and parent or guardian.
  • Age 10 \- 14 years.
  • Proven exercise\-induced asthma with a decrease in FEV1 of \>12%.
  • Background medicine: inhaled corticosteroid therapy (equivalent to max 400\-800mikg budesonide daily or equipotent doses).
  • FEV1 baseline \= 85% of predicted normal value.
  • Participants must be able to swallow a medicine capsule.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 32
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range

Exclusion Criteria

  • Inability to use the study equipment correctly.
  • Treatment with long acting beta2\-agonists.
  • Changing the background medication during the study period.
  • Short\-acting beta2\-agonists must not be used within 8 hours before the running test.
  • Antihistamines must not be used within 72 hours before the running test.
  • Hereditary galactose intolerance.
  • If the child is receiving regular montelukast, this treatment must be stopped within two weeks before the commencement of the trial.
  • Temperature above 38\.5 or infection\-related respiratory symptoms on days with scheduled running test.

Outcomes

Primary Outcomes

Not specified

Similar Trials